IKS014 in Advanced Solid Tumors That Express HER2
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low... [+17]
History of (noninfectious) ILD/pneumonitis that required steroids, has current I... [+15]